Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor (Q34041792)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor (English)

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

1 reference

based on heuristic

inferred from title

B-cell lymphoma

1 reference

based on heuristic

inferred from title

diffuse large B-cell lymphoma

1 reference

based on heuristic

inferred from title

Steven Rosenberg

26

object named as

Steven A Rosenberg

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

author name string

James N Kochenderfer

1

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Mark E Dudley

2

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sadik H Kassim

3

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Robert P T Somerville

4

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Robert O Carpenter

5

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Maryalice Stetler-Stevenson

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

James C Yang

7

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Giao Q Phan

8

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Marybeth S Hughes

9

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Richard M Sherry

10

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Mark Raffeld

11

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Steven Feldman

12

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Lily Lu

13

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Yong F Li

14

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Lien T Ngo

15

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Andre Goy

16

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Tatyana Feldman

17

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

David E Spaner

18

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Michael L Wang

19

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Clara C Chen

20

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sarah M Kranick

21

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Avindra Nath

22

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Debbie-Ann N Nathan

23

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Kathleen E Morton

24

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Mary Ann Toomey

25

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

language of work or name

0 references

publication date

25 August 2014

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

33

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

540-549

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Design and development of therapies using chimeric antigen receptor-expressing T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Recent advances in the management of mantle cell lymphoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

History of myeloid-derived suppressor cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Donor-derived CD19-targeted T cells cause regression of malignancy persisting after allogeneic hematopoietic stem cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Gene-engineered T cells for cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

The basic principles of chimeric antigen receptor design

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Chimeric antigen receptor (CAR)-specific monoclonal antibody to detect CD19-specific T cells in clinical trials

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

B-cell maturation antigen is a promising target for adoptive T-cell therapy of multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Changing role of stem cell transplantation in follicular lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Myeloid-derived suppressor cells in cancer patients: a clinical perspective.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Relapsed/refractory diffuse large B-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Immunomodulatory therapy of cancer with T cell-engaging BiTE antibody blinatumomab

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

CD57+ T lymphocytes and functional immune deficiency.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Central memory and effector memory T cell subsets: function, generation, and maintenance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

5 July 2018

Outcomes of patients with relapsed/refractory diffuse large B-cell lymphoma with progression of lymphoma after autologous stem cell transplantation in the rituximab era.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

28 October 2018

Response to second-line therapy defines the potential for cure in patients with recurrent diffuse large B-cell lymphoma: implications for the development of novel therapeutic strategies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

28 October 2018

Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

28 October 2018

Revised response criteria for malignant lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

28 October 2018

Ex vivo identification, isolation and analysis of tumor-cytolytic T cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

28 October 2018

Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

28 October 2018

T-cell clones can be rendered specific for CD19: toward the selective augmentation of the graft-versus-B-lineage leukemia effect

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4322257

28 October 2018

Detailed studies on expression and function of CD19 surface determinant by using B43 monoclonal antibody and the clinical potential of anti-CD19 immunotoxins

1 reference

https://pubmed.ncbi.nlm.nih.gov/25154820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/25154820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up

1 reference

https://pubmed.ncbi.nlm.nih.gov/25154820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL

1 reference

https://pubmed.ncbi.nlm.nih.gov/25154820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Diffuse large B-cell lymphoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/25154820

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2014.56.2025

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34041792&oldid=1979004335"